Login Register
Feed Contact Us
Invite People

Share 4Engineers with your friends and help them get started!

Emails
Enter multiple email addresses by separating it with a comma.
Advanced Search
Back
4Engineers
· Chemical Engineering Online
AI summary

Eli Lilly has signed a definitive agreement to acquire Merida Biosciences, a Cambridge, MA biotech developing precision biologics that selectively degrade pathogenic autoantibodies to treat serious autoimmune and allergic diseases.

How could targeted degradation of disease-causing autoantibodies reshape treatment for autoimmune and allergic conditions, and what milestones would you watch for following this acquisition?

Ely Lilly to acquire biotechnology company Merida Biosciences

This article was originally posted on chemengonline.com.
View article ->

Eli Lilly and Company (NYSE: LLY; Indianapolis, Ind.) and Merida Biosciences, Inc. (Cambridge, Mass.), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies — the disease-causing agents behind […]

The post Ely Lilly to acquire biotechnology company Merida Biosciences appeared first on Chemical Engineering.

Login to comment

Login

Related Conversations

Recent Conversations

Your Conversations

Report content
Reason Description